Home › Lexicon Announces Focus On Late-Stage Development Programs And Preparation For Commercialization
 

Keywords :   


Lexicon Announces Focus On Late-Stage Development Programs And Preparation For Commercialization

2014-02-05 07:12:10| drugdiscoveryonline News Articles

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today it is focusing its resources on its late-stage drug development programs, principally LX4211 for diabetes and telotristat etiprate (LX1032) for carcinoid syndrome, and preparation for the transition to commercialization

Tags: development focus programs preparation

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07Hurricane Beryl Graphics
03.07Hurricane Beryl Forecast Discussion Number 18
03.07Hurricane Beryl Wind Speed Probabilities Number 18
03.07Hurricane Beryl Public Advisory Number 18
03.07Summary for Hurricane Beryl (AT2/AL022024)
03.07Hurricane Beryl Forecast Advisory Number 18
03.07Hurricane Beryl Graphics
03.07Atlantic Tropical Weather Outlook
More »